{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:17:47Z","timestamp":1785842267417,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ygyno.2017.02.010","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T03:05:05Z","timestamp":1489115105000},"page":"230-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer"],"prefix":"10.1016","volume":"145","author":[{"given":"Renee A.","family":"Cowan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane Gerda Zahl","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Mario M.","family":"Leitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem R.","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ygyno.2017.02.010_bb0005","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.6004\/jnccn.2013.0142","article-title":"Ovarian cancer, version 2.2013: featured updates to the NCCN guidelines","volume":"11","author":"Morgan","year":"2013","journal-title":"JNCCN Journal of the National Comprehensive Cancer Network"},{"issue":"9375","key":"10.1016\/j.ygyno.2017.02.010_bb0010","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2017.02.010_bb0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","author":"Aghajanian","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.ygyno.2017.02.010_bb0020","first-page":"189","article-title":"Survival of patients following secondary cytoreductive surgery in ovarian cancer","volume":"61","author":"BEREK","year":"1983","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.02.010_bb0025","first-page":"6","article-title":"Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer","author":"Galaal","year":"2010","journal-title":"Cochrane database of systematic reviews (Online)"},{"issue":"1","key":"10.1016\/j.ygyno.2017.02.010_bb0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2017.02.010_bb0035","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2017.02.010_bb0040","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.02.010_bb0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.02.010_bb0050","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ygyno.2004.01.029","article-title":"Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach","volume":"94","author":"Chi","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.02.010_bb0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2017.02.010_bb0060","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2014.01.027","article-title":"Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer","volume":"132","author":"Harter","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.02.010_bb0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IGC.0000000000000051","article-title":"Secondary complete cytoreduction in recurrent ovarian cancer: benefit of optimal patient selection using scoring system","volume":"24","author":"Laas","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2017.02.010_bb0070","first-page":"3423","article-title":"AGO score as a predictor of surgical outcome at secondary cytoreduction in patients with ovarian cancer","volume":"35","author":"Muallem","year":"2015","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2017.02.010_bb0075","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2015.02.004","article-title":"External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer","volume":"137","author":"Van De Laar","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.010_bb0080","series-title":"A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre","author":"Angioli","year":"2015"},{"key":"10.1016\/j.ygyno.2017.02.010_bb0085","first-page":"1","article-title":"Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers","author":"Minaguchi","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"issue":"282","key":"10.1016\/j.ygyno.2017.02.010_bb0090","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"issue":"19","key":"10.1016\/j.ygyno.2017.02.010_bb0095","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2207::AID-SIM920>3.0.CO;2-Y","article-title":"Assessing screening tests: extensions of McNemar's test","volume":"17","author":"Lachenbruch","year":"1998","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2017.02.010_bb0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/ptj\/85.3.257","article-title":"The kappa statistic in reliability studies: use, interpretation, and sample size requirements","volume":"85","author":"Sim","year":"2005","journal-title":"Phys. Ther."},{"issue":"6","key":"10.1016\/j.ygyno.2017.02.010_bb0105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11912-012-0260-x","article-title":"Surgery for relapsed ovarian cancer: when should it be offered?","volume":"14","author":"Harter","year":"2012","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.ygyno.2017.02.010_bb0110","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3816\/COC.2008.n.009","article-title":"Making of a phase III study in recurrent ovarian cancer: the odyssey of GOG 213","volume":"1","author":"Coleman","year":"2008","journal-title":"Clinical Ovarian Cancer"},{"key":"10.1016\/j.ygyno.2017.02.010_bb0115","first-page":"14(1)","article-title":"Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): A multicenter randomised controlled study","author":"Van de Laar","year":"2014","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2017.02.010_bb0120","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical trials in recurrent ovarian cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2017.02.010_bb0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2014.09.017","article-title":"Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial","volume":"136","author":"Lee","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.02.010_bb0130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2016.01.027","article-title":"Performance of AGO score for secondary cytoreduction in a high-volume U.S. center","volume":"141","author":"Janco","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.02.010_bb0135","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1023\/A:1008323922057","article-title":"Consensus statements","volume":"10","author":"Berek","year":"1999","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2017.02.010_bb0140","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.20106","article-title":"Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?","volume":"100","author":"Zang","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.02.010_bb0145","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","author":"Al","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.ygyno.2017.02.010_bb0150","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IGC.0b013e31821743f9","article-title":"Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer","volume":"21","author":"Frederick","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2017.02.010_bb0155","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncr.22447","article-title":"Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome","volume":"109","author":"Salani","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2017.02.010_bb0160","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2017.02.010_bb0165","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.010_bb0170","first-page":"1","article-title":"Volume-based quantitative FDG PET\/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery","author":"Vargas","year":"2015","journal-title":"Eur. Radiol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581730121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581730121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T17:32:12Z","timestamp":1601746332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581730121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S009082581730121X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}